Generation of Gene-Modified T Cells Reactive against the Angiogenic Kinase Insert Domain-Containing Receptor (KDR) Found on Tumor Vasculature

Abstract

The destruction of newly forming tumor vasculature is a promising approach to inhibit tumor growth. The goal of the present study was to investigate whether human lymphocytes gene modified to express a chimeric receptor specific for the angiogenic endothelial cell receptor, KDR, could react against KDR⁺ cells. Gene-modified lymphocytes specifically lysed KDR⁺ cells and secreted cytokines in response to KDR⁺ target cells including human umbilical vein endothelial cells (HUVECs). Anti-KDR lymphocytes induced HUVECs to secrete the chemokine interleukin 8 and upregulate the adhesion molecules VCAM and E-selectin, which may be important in the recruitment of further immune effector cells to tumor. These KDR-specific lymphocytes may be useful in the adoptive immunotherapy of a broad range of cancers by inducing immune-mediated destruction of tumor neovasculature.